Product List of Pharmaceutical
As a specialized, R&D-centered operation, the development of new world-class drugs is advanced to offer innovative and unique therapeutic solutions in the fields of orthopedics, critical/intensive care, urology, the immune system, and the central nervous system. September 2026, the main pharmaceutical operations in the U.S. and Europe adopted the unified brand of 91³Ô¹Ï Therapeutics.
primary
Prescription drugs
default
2
Envarsus XR® (tacrolimus extended-release tablets)
Tarpeyo® (budesonide) delayed release capules
spacer
spacer
default
3
TERIBONEâ„¢ (teriparatide acetate)
Teriboneâ„¢ is a human parathyroid hormone preparation that facilitates bone formation, for the indication of osteoporosis with weekly or twice weekly subcutaneous injections.
RECLASTâ„¢ (zoledronic acid)
Reclastâ„¢ is a bisphosphonate agent that suppresses bone resorption, for the treatment of osteoporosis with once-a-year intravenous infusion. Reclastâ„¢ is a registered trademark of Novartis.
RECOMODULINâ„¢ (thrombomodulin alpha)
Recomodulinâ„¢ is a thrombomodulin agent produced through genetic engineering, indicated for the treatment of disseminated intravascular coagulation (DIC) associated with malignant tumors, infectious diseases, etc.
KEVZARA® (sarilumab)
Kevzara® is a human monoclonal antibody that blocks the action of IL-6, for the treatment of rheumatoid arthritis. Kevzara® is a registered trademark of Sanofi Biotechnology.
PLAQUENIL® (hydroxychloroquine sulfate)
Plaquenil® is an immunomodulator indicated for the treatment of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). Plaquenil® is a registered trademark of Sanofi-Aventis U.S.
DOPTELET® (avatrombopag maleate)
Doptelet® is a thrombopoietin receptor agonist, which is an agent for improving thrombocytopenia in patients with chronic liver disease who are scheduled to undergo an invasive procedure. 91³Ô¹Ï Therapeutics obtained exclusive distribution rights in Japan for Doptelet® for thrombocytopenia associated with chronic liver disease from Swedish Orphan Biovitrum Japan Co., Ltd.
CRESEMBA™（isavuconazonium sulfate）
Cresembaâ„¢ is an azole antifungal drug for fungal infections, such as Aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma), Mucormycosis, and Cryptococcosis (pulmonary cryptococcosis, disseminated cryptococcosis (including cryptococcal meningitis))
EMPAVELI® (pegcetacoplan)
Empaveli® is a PEGylated peptide1 inhibiting the function of complement protein C3 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). 91³Ô¹Ï Therapeutics obtained exclusive distribution rights in Japan for Empaveli® for PNH from Swedish Orphan Biovitrum Japan Co., Ltd.
spacer
For information on our pharmaceutical business in the United States and Europe, please visit the websites of 91³Ô¹Ï Therapeutics Inc. and Calliditas Therapeutics AB.
button
2
91³Ô¹Ï Therapeutics Inc. website (External Link)
Calliditas Therapeutics AB website (External Link)
spacer